Teva Pharmaceutical has agreed to pay an $85 million settlement with the state of Oklahoma. The announcement comes just before the company was going to face trial over allegations that it and other drugmakers helped fuel the U.S. opioid epidemic.
Teva, the world’s largest generic drugmaker, said the settlement “does not establish any wrongdoing on the part of the company” and denied contributing to opioid abuse in Oklahoma. Claims against Teva focused on the branded opioid products Actiq and Fentora as well as generic painkillers it produced.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
TEVA moved below its 50-day moving average on November 19, 2026 date and that indicates a change from an upward trend to a downward trend. In 25 of 35 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 71%.
The 10-day RSI Indicator for TEVA moved out of overbought territory on November 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 49 similar instances where the indicator moved out of overbought territory. In 24 of the 49 cases, the stock moved lower in the following days. This puts the odds of a move lower at 49%.
The Momentum Indicator moved below the 0 level on November 19, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TEVA as a result. In 51 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 65%.
The Moving Average Convergence Divergence Histogram (MACD) for TEVA turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 24 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 59%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TEVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +2.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where TEVA advanced for three days, in 232 of 302 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
TEVA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 218 of 283 cases where TEVA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
The Tickeron Profit vs. Risk Rating rating for this company is 6 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. TEVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 72 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.410) is normal, around the industry mean (6.379). P/E Ratio (68.726) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.980) is also within normal values, averaging (2.202). Dividend Yield (0.008) settles around the average of (0.061) among similar stocks. P/S Ratio (2.589) is also within normal values, averaging (183.387).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients
Industry PharmaceuticalsGeneric